Summary
Regeneron Pharmaceuticals, Inc. (REGN) has completed a $720 million lease financing transaction for its corporate headquarters and laboratory facilities located in Tarrytown, New York. This transaction involved a third-party lessor acquiring the facility, with Regeneron entering into a five-year lease agreement for the premises through a wholly-owned subsidiary. The company anticipates that the new lease arrangements will result in lower rent payments compared to previous leases and will be immediately accretive to earnings. This lease financing is structured in a way that it does not constitute indebtedness under Regeneron's existing Revolving Credit Facility. Consequently, the amounts outstanding under the lease financing do not impact the company's total leverage ratio or its borrowing capacity under the credit facility. The transaction also includes covenants and terms that are substantially similar to those in its existing Credit Agreement, ensuring consistency in financial and operational management. The lease term is five years with an option to extend, and options to purchase or sell the facility are also available.
Key Highlights
- 1Completed a $720 million lease financing for its corporate headquarters and laboratory facilities.
- 2Regeneron's subsidiary leased the facility from a third-party lessor for a five-year term.
- 3The new lease is expected to result in lower rent payments and be immediately accretive to earnings.
- 4The lease financing does not count as indebtedness under the company's Revolving Credit Facility, preserving borrowing capacity.
- 5Financial and operating covenants are largely consistent with the existing Credit Agreement.
- 6The company and its subsidiaries provided a joint and several guaranty for the lessee's obligations.
- 7The lease includes options for extension, purchase, or sale of the facility.